Literature DB >> 22791475

Mycobacterium avium infection improved by microbial substitution of fungal infection.

Shuichi Yano1.   

Abstract

We reported a case of Mycobacterium avium infection in which disease activity appeared to have been suppressed after fungal infection. After the increase in β-D-glucan, her symptoms of fever and chest pain disappeared. We think this phenomenon may be microbial substitution and mild fungal infection may improve the activity due to M avium.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 22791475      PMCID： PMC3027508          DOI： 10.1136/bcr.02.2010.2776

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  10 in total

1.  A four-drug regimen for initial treatment of cavitary disease caused by Mycobacterium avium complex.

Authors:  C H Ahn; S S Ahn; R A Anderson; D T Murphy; A Mammo
Journal:  Am Rev Respir Dis       Date:  1986-09

2.  Evaluation of the diagnostic value of the measurement of (1-->3)-beta-D-glucan in patients with pulmonary aspergillosis.

Authors:  K Yuasa; H Goto; M Iguchi; T Okamura; R Ieki
Journal:  Respiration       Date:  1996       Impact factor: 3.580

3.  Comparison of antituberculosis drug regimens for lung disease caused by Mycobacterium avium complex.

Authors:  M Tsukamura; S Ichiyama
Journal:  Chest       Date:  1988-04       Impact factor: 9.410

4.  Evaluation of a (1->3)-beta-D-glucan assay for diagnosis of invasive fungal infections.

Authors:  Jerry W Pickering; Howard W Sant; Catherine A P Bowles; William L Roberts; Gail L Woods
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

5.  First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol.

Authors: 
Journal:  Thorax       Date:  2001-03       Impact factor: 9.139

6.  Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease.

Authors:  D E Griffith; B A Brown; W M Girard; B E Griffith; L A Couch; R J Wallace
Journal:  Clin Infect Dis       Date:  2001-05-04       Impact factor: 9.079

7.  Pulmonary disease caused by Mycobacterium avium-intracellulare in HIV-negative patients: five-year follow-up of patients receiving standardised treatment.

Authors: 
Journal:  Int J Tuberc Lung Dis       Date:  2002-07       Impact factor: 2.373

8.  Reappraisal of the serum (1-->3)-beta-D-glucan assay for the diagnosis of invasive fungal infections--a study based on autopsy cases from 6 years.

Authors:  Taminori Obayashi; Kumiko Negishi; Tomokazu Suzuki; Nobuaki Funata
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

9.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

10.  Medical therapy of Mycobacterium avium-intracellulare pulmonary disease.

Authors:  E T Etzkorn; S Aldarondo; C K McAllister; J Matthews; A J Ognibene
Journal:  Am Rev Respir Dis       Date:  1986-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.